JP2021535761A5 - - Google Patents
Info
- Publication number
- JP2021535761A5 JP2021535761A5 JP2021539337A JP2021539337A JP2021535761A5 JP 2021535761 A5 JP2021535761 A5 JP 2021535761A5 JP 2021539337 A JP2021539337 A JP 2021539337A JP 2021539337 A JP2021539337 A JP 2021539337A JP 2021535761 A5 JP2021535761 A5 JP 2021535761A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- protein according
- spd
- domain
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731488P | 2018-09-14 | 2018-09-14 | |
| US62/731,488 | 2018-09-14 | ||
| US201962888320P | 2019-08-16 | 2019-08-16 | |
| US62/888,320 | 2019-08-16 | ||
| PCT/US2019/050742 WO2020056085A1 (en) | 2018-09-14 | 2019-09-12 | Spd-1 variant - fc fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021535761A JP2021535761A (ja) | 2021-12-23 |
| JP2021535761A5 true JP2021535761A5 (cg-RX-API-DMAC7.html) | 2022-09-07 |
Family
ID=68211179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539337A Pending JP2021535761A (ja) | 2018-09-14 | 2019-09-12 | sPD−1バリアント−Fc融合タンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11498955B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3850003A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021535761A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210058902A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112969710A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019338416A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3109983A1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ774126A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202101904UA (cg-RX-API-DMAC7.html) |
| TW (2) | TW202348622A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020056085A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016164428A1 (en) * | 2015-04-06 | 2016-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway |
| EP3991741A1 (en) * | 2020-11-02 | 2022-05-04 | Klinikum rechts der Isar der Technischen Universität München | An immune checkpoint-modulating vsv-ndv hybrid virus for oncolytic virus immonotherapy of cancer |
| US20230414660A1 (en) * | 2020-11-13 | 2023-12-28 | Ludwig Institute For Cancer Research Ltd | Pd-1 decoy variants for immunotherapy |
| WO2022137186A1 (en) | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor |
| CN117321079A (zh) * | 2021-01-11 | 2023-12-29 | 优特力克斯有限公司 | 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途 |
| EP4288080A1 (en) * | 2021-02-04 | 2023-12-13 | Helsingin Yliopisto | A cross-hybrid fc-fusion polypeptide targeting pd-l1 and methods and uses related thereto |
| WO2022187488A2 (en) * | 2021-03-03 | 2022-09-09 | Shattuck Labs, Inc. | Mutant pd-1 extracellular domains |
| US20220387488A1 (en) | 2021-05-12 | 2022-12-08 | Crispr Therapeutics Ag | Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies |
| EP4346875A4 (en) * | 2021-05-28 | 2025-04-16 | Akso Biopharmaceutical, Inc. | BISPECIFIC FC FUSION PROTEINS WITH SPD-1 AND IL-15 |
| KR20230044131A (ko) * | 2021-09-24 | 2023-04-03 | 바이오엔시스템스 주식회사 | Pd-1 및 il-15를 포함하는 융합단백질 이량체 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110034373A1 (en) * | 2007-08-03 | 2011-02-10 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
| CN103261217B (zh) * | 2010-11-11 | 2017-04-26 | 港大科桥有限公司 | 可溶性 pd‑1变体、融合构建体及其用途 |
| US20150368316A1 (en) * | 2013-02-07 | 2015-12-24 | Albert Einstein College Of Medicine Of Yeshiva University | A selective high-affinity immune stimulatory reagent and uses thereof |
| WO2016023001A1 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| EP3177640B1 (en) * | 2014-08-08 | 2020-05-06 | The Board of Trustees of the Leland Stanford Junior University | High affinity pd-1 agents and methods of use |
| WO2016164428A1 (en) * | 2015-04-06 | 2016-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway |
| US10844392B2 (en) * | 2015-06-05 | 2020-11-24 | Ibio, Inc. | Materials and methods for producing endostatin fusion polypeptides in plant cells |
| PL3368572T5 (pl) * | 2015-10-02 | 2026-07-20 | Les Laboratoires Servier | Przeciwciała anty-PD-1 oraz kompozycje |
| WO2017123548A1 (en) | 2016-01-14 | 2017-07-20 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment |
| WO2018104473A1 (en) * | 2016-12-07 | 2018-06-14 | Oslo Universitetssykehus Hf | Compositions and methods for cell therapy |
| WO2019241758A1 (en) * | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
-
2019
- 2019-09-12 KR KR1020217010801A patent/KR20210058902A/ko not_active Ceased
- 2019-09-12 US US16/569,105 patent/US11498955B2/en active Active
- 2019-09-12 JP JP2021539337A patent/JP2021535761A/ja active Pending
- 2019-09-12 CA CA3109983A patent/CA3109983A1/en active Pending
- 2019-09-12 CN CN201980060042.5A patent/CN112969710A/zh active Pending
- 2019-09-12 TW TW112132395A patent/TW202348622A/zh unknown
- 2019-09-12 EP EP19786693.2A patent/EP3850003A1/en not_active Withdrawn
- 2019-09-12 WO PCT/US2019/050742 patent/WO2020056085A1/en not_active Ceased
- 2019-09-12 AU AU2019338416A patent/AU2019338416A1/en not_active Abandoned
- 2019-09-12 NZ NZ774126A patent/NZ774126A/en not_active IP Right Cessation
- 2019-09-12 TW TW108133070A patent/TWI815964B/zh not_active IP Right Cessation
- 2019-09-12 SG SG11202101904UA patent/SG11202101904UA/en unknown
-
2022
- 2022-10-10 US US17/962,983 patent/US20230131056A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022504550A5 (cg-RX-API-DMAC7.html) | ||
| JP2022115876A5 (cg-RX-API-DMAC7.html) | ||
| CN103554235B (zh) | MERS-CoV病毒膜蛋白中的RBD片段及其编码基因和应用 | |
| JP2025184979A5 (cg-RX-API-DMAC7.html) | ||
| JP2014533518A5 (cg-RX-API-DMAC7.html) | ||
| RU2019139064A (ru) | Композиции и способы для лечения цитомегаловируса | |
| JP2013027391A5 (cg-RX-API-DMAC7.html) | ||
| JP2012152218A5 (cg-RX-API-DMAC7.html) | ||
| JP2017514522A5 (cg-RX-API-DMAC7.html) | ||
| CN114409770B (zh) | 一种裂谷热病毒人源单克隆抗体及其应用 | |
| JP2024180560A5 (cg-RX-API-DMAC7.html) | ||
| JP2023522154A5 (cg-RX-API-DMAC7.html) | ||
| AU2016313660B2 (en) | Polypeptide carrier for presenting target polypeptide and uses thereof | |
| Wang et al. | Expression, purification, and immunogenic characterization of Epstein–Barr virus recombinant EBNA1 protein in Pichia pastoris | |
| JP2026075092A (ja) | ワクシニアウイルスポリメラーゼ媒介性ウイルス複製 | |
| JP2025537544A5 (ja) | 融合タンパク質及びそれを含む粒子状抗原 | |
| Bentz et al. | KSHV LANA and EBV LMP1 induce the expression of UCH-L1 following viral transformation | |
| JP2011530277A5 (cg-RX-API-DMAC7.html) | ||
| CN103333255A (zh) | 一种长效hiv‐1膜融合抑制剂 | |
| RU2021110064A (ru) | ГИБРИДНЫЕ БЕЛКИ ВАРИАНТА sPD-1—FC | |
| Verheije et al. | Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter | |
| RU2546242C1 (ru) | РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 18 | |
| JP2024516320A5 (cg-RX-API-DMAC7.html) | ||
| CN103243115A (zh) | 一种诺如病毒多表位抗原基因 | |
| CN104561022B (zh) | 家猪肿瘤坏死因子突变体的构建及蛋白表达纯化方法 |